BSX
A tiny trim, not a full haircut
Truist isn’t exactly sprinting for the exits here. It shaved Boston Scientific’s price target to $90 from $92, but kept the Buy rating in place — the investing equivalent of saying, “I’m still coming to the party, I’m just eating one fewer slice of pizza.”
The stock has already been taking a beating, recently hovering around $64.57 and hanging out near its 52-week low. So this note lands more as a reminder that expectations are fragile than as a fresh panic button.
Watchman is doing the heavy lifting
The bigger issue is what happens inside Boston Scientific’s cardiovascular business, especially Watchman and electrophysiology. Truist expects:
- Watchman growth of about 18% year over year, below the roughly 22% consensus view
- Electrophysiology to land more or less in line
- First-quarter results on April 22 to stay within company guidance, even if the market gets twitchy about the details
That’s the kind of setup investors hate: the headline may be fine, but one soft-ish segment can hijack the whole conversation.
The 2026 guidance question mark
Truist also floated the idea that management could lower 2026 organic revenue guidance to around 8% or higher, down from the current 10% to 11% range. If that happens, the market probably won’t throw a confetti parade.
The firm pointed to CLOSURE-AF as a possible drag on Watchman momentum, while March 2026 CHAMPION trial results could help cushion the blow later on. Translation: one part of the story may be slowing down, but the next catalyst is still somewhere down the road.
Big picture: this is still a bullish note with a slightly more skeptical haircut. For investors, the real question is whether Boston Scientific can keep the growth machine humming without forcing guidance to come back to earth.